The effect of age on opioid switching to methadone: A systematic review

Journal of Palliative Medicine

Volumn 15, Issue 3, 2012, Pages 347-351

  Mercadante, Sebastiano ^a   Bruera, Eduardo ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENTANYL; METHADONE; MORPHINE; OPIATE; OXYCODONE;

ADVANCED CANCER; AGE DISTRIBUTION; DRUG EFFECT; DRUG SUBSTITUTION; HUMAN; HYPERALGESIA; KIDNEY FUNCTION; OUTCOME ASSESSMENT; PAIN; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

AGE FACTORS; ANALGESICS, OPIOID; DRUG SUBSTITUTION; HUMANS; METHADONE; PAIN;

EID: 84858114891     PISSN: 10966218     EISSN: 15577740     Source Type: Journal    
DOI: 10.1089/jpm.2011.0198     Document Type: Review

References (43)

1. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V; Expert Working Group of the European Association of Palliative Care Network: Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-2554.
2. Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 2: Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001;21:255-264 (Pubitemid 32192946)
3. de Stoutz N, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-384.
4. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78;852-857. (Pubitemid 26268617)
5. Mercadante S, Bruera E: Opioid switching: A systematic and critical review. Cancer Treat Rev 2006;32:304-315. (Pubitemid 44502005)
6. Mercadante S: Opioidi rotation: Opioid rotation in cancer pain: Rationale and clinical aspects. Cancer 1999;86:1856-1866.
7. Slatkin N: Opioid switching and rotation in primary care: Implementation and clinical utility. Curr Med Res Opin 2009;25:2133-2159.
8. Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004;(3):CD004847.
9. Weschules D, Bain K: A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 2008;9:595-612.
10. Knotkova H, Fine P, Portenoy RK: Opioid rotation: The science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009;38:426-439.
11. Fine PG, Portenoy RK: Establishing best practices for opioid rotation: Conclusions of an expert panel. J Pain Symptom Manage 2009;38:418-425.
12. Ross JR, Riley J, Quigley C, Welsh KI: Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist 2006;11:765-773. (Pubitemid 44157564)
13. Mercadante S. Arcuri E: Pharmacological management of cancer pain in the elderly. Drugs Aging 2007;24:761-776. (Pubitemid 47378290)
14. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78;852-857. (Pubitemid 26268617)
15. Bruera E, Watanabe S, Fainsinger R, Spachynski K, Suarez- Almazor M, Inturrisi C: Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995;62:141-146.
16. Lawlor R, Turner K, Hanson J: Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain 1997;72:79-85. (Pubitemid 27321904)
17. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F: Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? J Clin Oncol 1998;16:3216-3221. (Pubitemid 28481614)
18. Ripamonti C, De Conno F, Groff L, Belzile M, Pereira J, Hanson J, Bruera E: Equianalgesic dose/ratio between methadone and other opioid agonists in cancer pain: comparison of two clinical experiences. Ann Oncol 1998;9:79-83. (Pubitemid 28125768)
19. Hagen N, Wasylenko E: Methadone: Outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 1999;18:369-375. (Pubitemid 29528473)
20. Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999;18: 120-125. (Pubitemid 29409440)
21. Scholes C, Gonty N, Trotman L: Methadone titration in opioid-resistant cancer pain. Eur J Cancer Care 1999;8:26-29.
22. Cubero DI, del Giglio A: Early switching from morphine to methadone is not improved by acetaminophen in the analgesia of oncologic patients: A prospective, randomized, double-blind, placebo-controlled study. Support Care Cancer 2010;18:235-242.
23. Mercadante S, Casuccio A, Calderone L: Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999;17:3307-3312. (Pubitemid 29470667)
24. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C: Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: A prospective study. J Clin Oncol 2001;19:2898-2904. (Pubitemid 32538200)
25. Santiago-Palma J, Khojainova N, Kornick C, Fischberg DJ, Primavera LH, Payne R, Manfredi P: Intravenous methadone in the management of chronic cancer pain: Safe and effective starting doses when substituting methadone for fentanyl. Cancer 2001;92:1919-1925. (Pubitemid 32952512)
26. Mercadante S, Bianchi M, Villari P, Ferrera P, Casuccio A, Fulfaro F, Gebbia V: Opioid plasma concentration during switching from morphine to methadone: Preliminary data. Support Care Cancer 2003;11:326-331. (Pubitemid 36723561)
27. Tse D, Sham M, Ma H: An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: An open uncontrolled prospective study in a Chinese population. Palliat Med 2003;17:206-211. (Pubitemid 36432599)
28. Benitez-Rosario MA, Ferla M, Salinas-Martin A, Martinez- Castillo LP, Martin-Ortega JJ: Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 2004;101:2866-2873. (Pubitemid 39603196)
29. Mercadante S, Ferrera P, Villari P, Casuccio A: Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005;23:5229-5234. (Pubitemid 46224034)
30. Hernansanz S, Gutierrez C, Rubiales AS, Flores LA, del Valle ML: Opioid rotation to methadone at home. J Pain Symptom Manage 2006;31:2-4.
31. Mercadante S, Villari P, Ferrera P, Casuccio A, Gambaro V: Opioid plasma concentrations during a switch from transdermal fenatnyl to methadone. J Palliat Med 2007;10:338-344. (Pubitemid 46740206)
32. Benitez-Rosario M, Salinas-Martin A, Aguirre-Jaime A, Perez- Mendez L, Feria M: Morphine-methadone opioid rotation in cancer patients: analysis of dose predicting factors. J Pain Symptom Manage 2009;37:1061-1068.
33. Leppert W: The role of methadone in opioid rotation - A Polish experience. Support Care Cancer 2009;17:607-612.
34. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, Mangione S: Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 2009;37:632-641.
35. Parsons HA, de la Cruz M, El Osta B, Li Z, Calderon B, Palmer L, Bruera E: Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010;116:520-528.
36. Hall S, Gallagher R, Gracely E, Knowlton C, Weschules D: The terminal cancer patient: Effect of age, gender, and primary tumor site on opioid dose. Pain Med 2003;4:125-134.
37. Viganò A, Bruera E, Suarez-Almazor M: Age, pain intensity and opioid dose in patients with advanced cancer. Cancer 1998;83:1244-1250. (Pubitemid 28419080)
38. Mercadante S. Casuccio A, Pumo S, et al: Factors influencing the opioid response in advanced cancer patients with pain followed at home. The effects of age and gender. Support Care Cancer 2000;8:123-130. (Pubitemid 30114820)
39. Hall S, Gallagher R, Gracely E, Knowlton C,Weschules D: The terminal cancer patient: Effect of age, gender, and primary tumor site on opioid dose. Pain Med 2003;4:125-134.
40. Mercadante S, Villari P, Ferrera P, Casuccio A: Opioid escalation in patients with cancer pain: The effect of age. J Pain Symptom Manage 2006;32:413-419. (Pubitemid 44755107)
41. Mercadante S, Casuccio A, Agnello A, Barresi L: Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 1999;18:188-192. (Pubitemid 29459124)
42. Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hosp Palliat Care 2005;22:291-294. (Pubitemid 41039786)
43. Zimmermann C, Seccareccia D, Booth C, Cottrell W: Rotation to methadone after opioid dose escalation: How should individualization of dosing occur? J Pain Palliat Care Pharm 2005;19:25-31. (Pubitemid 41344305)